New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications


SMAD7 conditional knockout mice are available for licensing. SMAD7 can be knocked out by breeding with CRE-recombinase transgenic mice with a variety of promoters to yield tissue or cell type-specific deletions of SMAD7. SMAD7 has been shown to play a role in bone morphogenesis, cardiovascular tissue generation, immune regulation and fibrosis. Therefore, these mice provide a unique model to examine the role of the SMAD7 gene in disease processes that involve immunological, fibrotic, or cardiovascular components. Specifically, these mice may represent a novel model of Scleroderma, a disease with both an immunological and fibrotic component.

Potential Commercial Applications: Competitive Advantages:
  • Mouse model of Scleroderma
  • Means of studying bone morphogenesis and cardiovascular tissue generation
  • Means of studying the role of SMAD7 in immune regulation
 


Inventors:

Marilyn Diaz (NIEHS)  ➽ more inventions...


Intellectual Property:
Research Material -- patent protection is not being pursued for this technology

Publications:
Dong C, et al. PMID 11904440

Collaboration Opportunity:

The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Sharon Soucek, Ph.D. at sharon.soucek@nih.gov for more information.


Licensing Contact:
Vidita Choudhry, Ph.D.
Email: vidita.choudhry@nih.gov
Phone: 301-594-4095

OTT Reference No: E-040-2010-0
Updated: Sep 4, 2020